Status:
UNKNOWN
Role of Nesfatin-1 and Nicotinamide in Infertile Women With Polycystic Ovary Syndrome
Lead Sponsor:
Assiut University
Conditions:
PCOS
Eligibility:
FEMALE
18-40 years
Brief Summary
evaluation of the potential role of circulating Nesfatin-1 and Nicotinamide in patients with polycystic ovary syndrome. and detection the correlation between Nesfatin-1 and body mass index (BMI), Wai...
Detailed Description
* Nesfatin-1 is an 82-amino acid polypeptide derived from the nucleobindin 2 (NUCB2) precursor proteins. * It is a newly identified peptide. It is released from several tissues including forebrain, hi...
Eligibility Criteria
Inclusion
- PCOS patients in the age range 18 - 40 years old.
- Diagnosis of PCOS is based on the 2003 ESHRE/ASRM diagnostic criteria, according to which patients who had at least two of the following conditions are accepted as having PCOS:
- Oligo or anovulation, defined by the presence of oligomenorrhea or amenorrhea, confirmed by luteal progesterone and normal serum follicle stimulating hormone (FSH) levels (1.0-10.0 IU/L).
- Clinical hyperandrogenism signs which was defined as the presence of at least one of the following three features: hirsutism, acne, and androgenic alopecia. Biochemical hyperandrogenism was defined as a serum testosterone (T) level \>60 ng/dL (\>2.08 nmol/L).
- PCOS manifestation was defined as the presence of \>12 unilateral follicles 2-9 mm in size on the ovary or having the least unilateral ovary volume of 10 cm3 by ultrasonography (the measurement was performed when there was no follicle \>10 mm). Ovarian volume was calculated by the formula \[0.5× ovarian length × thickness × width\]. In the case of transabdominal ultrasonography, the presence of at least 10 unilateral antral follicles was required.
Exclusion
- Patients (age \<18 or \> 40years),
- Other endocrinology diseases as diabetes mellitus or thyroid disorders, Brain disorders as pituitary adenoma or tumour or brain tumours or masses,
- Chronic diseases such as cardiovascular, hepatic, hematologic, chronic renal failure, hypertension, and cancer,
- Use of oral contraceptives, antiandrogenics, glucocorticoids, antihypertensives, antidiabetics and anti-obesity drugs as well as the cigarettes, alcohol, and patients unwilling to participate in the study.
Key Trial Info
Start Date :
May 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2020
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT03870035
Start Date
May 1 2019
End Date
May 1 2020
Last Update
April 26 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.